Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) (HAL)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2009 by University of Texas Southwestern Medical Center.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Takeda Pharmaceuticals North America, Inc.
Information provided by:
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT01023620
First received: November 30, 2009
Last updated: December 1, 2009
Last verified: December 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2010
  Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)